No Data
No Data
While Shareholders of Capricor Therapeutics (NASDAQ:CAPR) Are in the Black Over 5 Years, Those Who Bought a Week Ago Aren't so Fortunate
Capricor Therapeutics to Participate in Upcoming Investor Conferences
8 Health Care Stocks Whale Activity In Today's Session
Maxim Group Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $25
Capricor Therapeutics: Promising Advances in Duchenne Cardiomyopathy Treatment Drive Buy Rating
Beyond The Numbers: 7 Analysts Discuss Capricor Therapeutics Stock
Green7plus : Please advise when it expects to FDA decision?
Trytosaveabit OP Green7plus : Haven’t seen a PDUFA date yet?